18F-FDG PET在原发性肺癌患者SABR后鉴别局部复发与炎性改变中的效用
本研究为双中心回顾性研究,纳入2012至2023年间接受SABR的754例连续肺癌患者,分析65例患者共74次FDG PET-CT扫描。结果显示复发灶SUVmax中位4.3,显著高于非复发灶的3.3(p=0.011);主观评分对复发的阳性与阴性预测值分别为0.45和0.96,仅纳入基线SUVmax>5.0的肿瘤时分别提升至0.94和1.00。作者认为FDG PET有助于指导SABR后疑似复发患者的管理,尤其对治疗前FDG高摄取的肿瘤。
要点
- SABR后复发灶SUVmax中位4.3,显著高于非复发灶的3.3(p=0.011)。
- 主观评分的阳性与阴性预测值分别为0.45和0.96,优于单独SUVmax。
- 仅纳入基线SUVmax>5.0的肿瘤时,阳性与阴性预测值分别提升至0.94和1.00。
核心结论
- FDG PET有助于指导SABR后疑似复发患者的管理,尤其对治疗前FDG高摄取的肿瘤。
研究设计与样本
- 双中心回顾性研究,纳入2012至2023年间在本机构接受SABR的754例连续肺病变患者。
- 分析65例患者共74次FDG PET-CT扫描,扫描中位时间为SABR后585天。
- 记录病灶SUVmax和复发可能性的主观评分,以随访影像、活检及切除组织学确定结局。
主要发现
- 74次FDG PET-CT扫描中,参考标准判定11次为局部复发、63次为非复发。
- 复发患者SABR后病灶SUVmax中位4.3(范围2.2-16.1),高于非复发患者的3.3(范围1.4-6.4),p=0.011。
- 主观评分的阳性预测值为0.45、阴性预测值为0.96;仅纳入基线SUVmax>5.0的肿瘤时分别提升至0.94和1.00。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic ablative radiotherapy (SABR) is used in patients with early-stage primary lung cancer who are not fit for surgery or who refuse surgery. Post-treatment, patients are monitored with surveillance CT, with [18F]FDG PET-CT often used for further investigation if there is suspicion of recurrence on CT. This study investigated the utility of [18F]FDG PET-CT in detecting recurrence in patients with suspicious CT findings. METHODS: This is a dual-centre retrospective study of 754 consecutive patients who received SABR for lung lesions in our institutions between 2012 and 2023. Seventy-four FDG PET-CT scans from 65 patients, performed at a median of 585 days after SABR were included. SUVmax and subjective score of likelihood of recurrence were recorded. Follow-up imaging, biopsy and resection histology, where available, were used to ascertain the patients' outcome. RESULTS: Out of 74 included FDG PET-CT scans, there were 11 local recurrences and 63 non-recurrences by reference standard. The SUVmax of the lesion post-SABR was significantly higher in patients who had recurrent tumour (median 4.3, range 2.2-16.1) compared to those who did not (median 3.3, range 1.4-6.4) (p = 0.011). Subjective scores of likelihood of recurrence performed better than SUVmax readings alone with positive and negative predictive values of 0.45 and 0.96, respectively, which are significantly improved to 0.94 and 1.00 when only including tumours with baseline SUVmax > 5.0. CONCLUSION: FDG PET is useful in guiding management of patients with suspected recurrence after SABR, particularly in cases where the tumour is FDG avid pre-treatment.
引用
- Fala M, Josephides E, Shah S, et al. The utility of [18F]FDG PET in discriminating between local recurrence and inflammatory changes following SABR in primary lung cancer patients. Eur J Nucl Med Mol Imaging. 2025. PMID: 40498157. doi:10.1007/s00259-025-07400-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。